Cover Image
市場調查報告書

全球多發性硬化症治療藥市場

Global Multiple Sclerosis Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 310827
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
全球多發性硬化症治療藥市場 Global Multiple Sclerosis Drugs Market 2014-2018
出版日期: 2014年08月20日 內容資訊: 英文 102 Pages
簡介

多發性硬化症,是發炎性的慢性疾病,導致脫髓鞘、神經軸突切斷、神經切斷。多發性硬化症,粗分為4個類型,即復發緩解型、次發漸進型、首發漸進型、漸進復發型。全球多發性硬化症治療藥市場,預計2013年∼2018年以CAGR 5.56%成長。

本報告提供全球多發性硬化症治療藥市場相關調查分析、市場規模與成長率、市場趨勢、推動市場要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 發病率和得病率

第8章 市場區隔:各分子類型

  • 生技藥品
  • 小分子

第9章 市場區隔:各給藥途徑

  • 口服藥
  • 非口服藥

第10章 地區區分

  • 美國

第11章 購買標準

第12章 推動市場成長要素

第13章 推動因素與其影響

第14章 市場課題

第15章 推動因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第19章 主要供應商分析

  • 產業概要、產業區分、主要資訊、SWOT分析等
    • Bayer
    • Biogen Idec
    • Merck Serono
    • Novartis
    • Teva Pharmaceuticals

第20章 相關報告

圖表

目錄
Product Code: IRTNTR3981

About Multiple Sclerosis and Disease Types

Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed in a patient with multiple sclerosis are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with the severe course of the disease can experience speech problems and movement problems. Multiple sclerosis can be broadly classified into four types: relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, and progressive-relapsing multiple sclerosis. On the basis of the route of drug administration, the Global Multiple Sclerosis Drugs market can be segmented into two: Oral Drugs, and Parenteral Drugs.

TechNavio's analysts forecast the Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis.

TechNavio's report, the Global Multiple Sclerosis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Multiple Sclerosis Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bayer
  • Biogen Idec
  • Merck Serono
  • Novartis
  • Teva Pharmaceutical

Other Prominent Vendors

  • AB Science
  • Abbvie
  • Acorda
  • Active Biotech
  • GlaxoSmithKline
  • Glenmark
  • Mitsubishi Tanabe
  • Opexa
  • Pfizer
  • Sanofi

Market Driver

  • Unmet Medical Needs

For a full, detailed list, view our report

Market Challenge

  • Unknown Etiology of the Disease

For a full, detailed list, view our report

Market Trend

  • Introduction of Disease-modifying Drugs

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

  • 04.1.1. Betaferon/Betaseron/Extavia
  • 04.1.2. Avonex/Rebif
  • 04.1.3. Fampyra
  • 04.1.4. Tecfidera
  • 04.1.5. Tysabri
  • 04.1.6. Gilenya
  • 04.1.7. Copaxone

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Rate of Incidence and Prevalence

08. Market Segmentation by Molecule Type

  • 08.1. Global Biologics Market
    • 08.1.1. Market Size and Forecast
  • 08.2. Global Small Molecules Market
    • 08.2.1. Market Size and Forecast

09. Market Segmentation by Route of Administration

  • 09.1. Global Oral Drugs Market
    • 09.1.1. Market Size and Forecast
  • 09.2. Global Parenteral Drugs Market
    • 09.2.1. Market Size and Forecast

10. Geographical Segmentation

  • 10.1. Multiple Sclerosis Market in the US
    • 10.1.1. Market Size and Forecast

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
    • 18.2.1. Bayer
    • 18.2.2. Biogen Idec
    • 18.2.3. Merck Serono
    • 18.2.4. Novartis
    • 18.2.5. Teva Pharmaceuticals
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Bayer
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Sales Segmentation by Business
    • 19.1.6. Sales by Geographical Segmentation
    • 19.1.7. Key Information
    • 19.1.8. SWOT Analysis
  • 19.2. Biogen Idec
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation by Revenue 2013
    • 19.2.4. Geographical Segmentation by Revenue 2013
    • 19.2.5. Business Strategy
    • 19.2.6. Key Developments
    • 19.2.7. SWOT Analysis
  • 19.3. Merck Serono
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Geographical Segmentation by Revenue 2013
    • 19.3.4. Business Strategy
    • 19.3.5. Recent Developments
    • 19.3.6. SWOT Analysis
  • 19.4. Novartis
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation by Revenue 2013
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Sales by Geography
    • 19.4.6. Business Strategy
    • 19.4.7. Key Developments
    • 19.4.8. SWOT Analysis
  • 19.5. Teva Pharmaceuticals
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation
    • 19.5.4. Business Segmentation by Revenue 2013
    • 19.5.5. Business Segmentation by Revenue 2012 and 2013
    • 19.5.6. Sales by Geography
    • 19.5.7. Business Strategy
    • 19.5.8. Key Developments
    • 19.5.9. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Multiple Sclerosis Drugs Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type
  • Exhibit 4: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013
  • Exhibit 5: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2018
  • Exhibit 6: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013-2018 (US$ billion)
  • Exhibit 7: Global Multiple Sclerosis Drugs Market Segmentation by Molecule Type 2013-2018 (in percent)
  • Exhibit 8: Global Biologics Market 2013-2018 (US$ billion)
  • Exhibit 9: Global Small Molecules Market 2013-2018 (US$ billion)
  • Exhibit 10: Global Multiple Sclerosis Drugs Market by Route of Administration
  • Exhibit 11: Global Multiple Sclerosis Drugs Market by Route of Administration 2013
  • Exhibit 12: Global Multiple Sclerosis Drugs Market by Route of Administration 2018
  • Exhibit 13: Global Multiple Sclerosis Drugs Market Segmentation by Route of Administration 2013-2018 (US$ billion)
  • Exhibit 14: Global Multiple Sclerosis Drugs Market Segmentation by Route of Administration 2013-2018 (in percent)
  • Exhibit 15: Global Oral Drugs Market 2013-2018 (US$ billion)
  • Exhibit 16: Global Parenteral Drugs Market 2013-2018 (US$ billion)
  • Exhibit 17: Global Multiple Sclerosis Drugs Market by Geography 2013
  • Exhibit 18: Multiple Sclerosis Market in the US 2013-2018 (US$ billion)
  • Exhibit 19: Global Multiple Sclerosis Drugs Market by Vendor Segmentation 2013
  • Exhibit 20: Global Sales Comparison of Betaseron/Betaferon 2010-2013 (US$ million)
  • Exhibit 21: Sales of Avonex 2011-2013 (US$ million)
  • Exhibit 22: Sales of Tysabri 2011-2013 (US$ million)
  • Exhibit 23: Sales of Fampyra 2011-2013 (US$ million)
  • Exhibit 24: Sales Comparison of Avonex, Tysabri and Fampyra 2011-2013 (US$ million)
  • Exhibit 25: Sales of Rebif 2010-2013 (US$ million)
  • Exhibit 26: Sales of Rebif in North America 2010-2013 (US$ million)
  • Exhibit 27: Sales of Rebif in Europe 2010-2013 (US$ million)
  • Exhibit 28: Sales of Rebif in Emerging Markets and RoW 2010-2013 (US$ million)
  • Exhibit 29: Geography-wise Sales of Rebif 2010-2013 (US$ million)
  • Exhibit 30: Sales of Gilenya 2010-2013 (US$ million)
  • Exhibit 31: Sales of Extavia 2010-2013 (US$ million)
  • Exhibit 32: Sales of Gilenya and Extavia 2010-2013 (US$ million)
  • Exhibit 33: Quarter-wise Sales of Copaxone 2011-2013 (US$ million)
  • Exhibit 34: Quarter-wise Sales of Copaxone in the US 2011-2013 (US$ million)
  • Exhibit 35: Quarter-wise Sales of Copaxone Outside the US 2011-2013 (US$ million)
  • Exhibit 36: Business Segmentation of Bayer AG 2013
  • Exhibit 37: Sales Comparison of Bayer AG by Business Segment 2012 and 2013 (US$ million)
  • Exhibit 38: Sales Segmentation of Bayer AG by Geography 2013
  • Exhibit 39: Biogen Idec: Business Segmentation by Revenue 2013
  • Exhibit 40: Biogen Idec: Geographical Segmentation by Revenue 2013
  • Exhibit 41: Merck Serono: Geographical Segmentation by Revenue 2013
  • Exhibit 42: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 43: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 44: Novartis AG: Sales by Geography 2013
  • Exhibit 45: Teva Pharmaceutical Industries Ltd.: Business Segmentation
  • Exhibit 46: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2013
  • Exhibit 47: Teva Pharmaceutical Industries Ltd.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 48: Teva Pharmaceutical Industries Ltd.: Sales by Geography 2013
Back to Top